MiyoSmart iQ (DIMS TED) is built upon one of the most extensively studied spectacle lens platforms in myopia management. Developed through a collaboration between HOYA

Vision Care and The Hong Kong Polytechnic University (PolyU), MiyoSmart incorporates defocus incorporated multiple segments (DIMS) technology, the result of more than a decade of research into optical approaches for slowing childhood myopia progression.

The landmark two-year randomised controlled trial (RCT), published in 2019, demonstrated a 59% reduction in myopia progression and a 60% reduction in axial elongation compared with single-vision lenses.1 Subsequent three-year and six-year follow-up studies confirmed that the treatment effect was sustained over time, with no evidence of rebound observed in long-term follow-up.2 An eight-year follow-up clinical study demonstrated that the myopia control effect of MiyoSmart spectacle lenses was sustained in those children who wore them continuously for up to eight years, suggesting that long-term use provides continued benefits to improve myopia management outcomes.3

These outcomes helped establish MiyoSmart as one of the most evidence-based spectacle lens interventions available for myopia management.

Figure 1. Global trends in myopia management, frequency of prescribing myopia correction options for progressing/young myopes by practitioners in different continents. IMI White Papers: 2016, 2019, and 2022.Available at myopiainstitute.org/imi-white-papers-clinical-summaries [accessed Jun 2026].

Figure 2. Comparisons of the average relative effects of the eccentricity of optically imposed defocus (+3.00D) on central refraction. Error bars ±1 SE. Adapted from Smith et al., 2020.7

Figure 3. Average effects of imposed positive defocus on axial length when different parts of the visual field were covered with a grey patch. The black line represents the effect of full field defocus. Error bars ±1 SE. ** p<0.01, *** p<0.001. Adapted from Swiatczak et al., 2024.9

However, clinical and research data indicate that treatment response can vary between children, reflecting the influence of multiple individual factors. These include age of myopia onset, level of myopia when starting intervention, and baseline progression rate, all of which may impact myopia control outcomes. Consistent with these observations, the development of MiyoSmart iQ focused on optimising the optical design to enhance the strength and consistency of the treatment effect across a broader paediatric population, as reflected in the high proportion of children showing minimal or no progression in the 12 month RCT.4

ADDRESSING VARIABILITY IN RESPONSE

Against this backdrop, HOYA’s research teams asked new questions: could the success of MiyoSmart be improved further? Could treatment efficacy become more consistent? Could younger children benefit?

The global rise in myopia is continuing at an alarming pace, with projections suggesting that nearly half of the world’s population could be affected by 2050.5 For eye care practitioners, the challenge has shifted from simple refractive correction to long-term risk reduction, recognising that progressive axial elongation during childhood is the key driver of future vision-threatening pathology. The urgency of early and effective intervention is widely acknowledged, yet variability in patient response continues to limit the effectiveness of current treatment strategies.

Figure 4. MiyoSmart iQ builds on HOYA’s proven DIMS technology with a refined TED design.

Spectacle lenses remain one of the most accessible and widely accepted approaches for paediatric myopia management, particularly in younger children.6 The introduction of defocus incorporated multiple segments (DIMS) technology marked a significant milestone, demonstrating that dual-focus spectacle lenses could deliver clinically meaningful reductions in myopia progression.

The development of MiyoSmart iQ represents a deliberate effort to move beyond established designs and address these limitations.

RETHINKING RETINAL CONTROL OF EYE GROWTH

The scientific understanding of myopia progression has evolved substantially in recent years, with increasing emphasis on the role of peripheral retinal signaling in regulating ocular growth.7,8 While central vision remains essential for visual acuity, it is now well established that eye growth is controlled by local retinal mechanisms responding to optical defocus.

Within this framework, the near-peripheral retina has attracted particular attention. Research indicates that retinal regions within approximately six to 10° eccentricity exhibit heightened sensitivity to defocus signals and may exert a strong influence on axial elongation.9 This area has been described in the paper as a functional ‘sweet spot’, where myopic defocus can effectively modulate eye growth, even when central vision remains clear.

Figure 5. No significant differences in distance visual acuity were observed among the three spectacle lens designs.

Experimental work in animal models has demonstrated that defocus applied to the macular region alone can influence refractive development, while electrophysiological studies in humans confirm differential retinal responses across eccentricity. These findings align with the concept that myopia progression is guided by cues from the near-peripheral retina rather than exclusively by foveal signals.

The biological mechanism underlying this response involves detection of myopic defocus, which triggers retinal signaling pathways that act through the choroid and sclera to slow axial elongation.10 Changes in choroidal thickness have emerged as a useful short-term biomarker of this process, with thickening associated with reduced ocular growth.

DIMS TECHNOLOGY WITH TRIPLE ENHANCED DESIGN

The original MiyoSmart lens was based on DIMS technology, combining a central optical zone with a surrounding treatment area composed of multiple defocus segments in a honeycomb distribution. This approach allows for simultaneous clear central vision and peripheral myopic defocus and has been supported by a substantial body of clinical evidence.

MiyoSmart iQ addresses key challenges through a triple enhanced design (TED), incorporating three key modifications: adding defocus segments closer to the geometric centre, increasing defocus power, and expanding the treatment zone.

Activated

A key concept underpinning MiyoSmart iQ is the continuous activation of the near-peripheral retina during both distance and near viewing.

During distance vision, pupil size plays an important role. When pupil diameter exceeds approximately 4 mm, a greater proportion of light rays passing through the defocus segments reaches the near-peripheral retina, activating the intended treatment zone. This effect ensures that the defocusing signal is not limited to peripheral vision but is also present when looking straight through the centre of the glasses.

MiyoSmart iQ brings the defocus segments closer to the visual axis, resizing the central clear zone from 9.4 mm to 6.9 mm. Defocus segments closer to the centre of the spectacle lens are intended to continuously activate the near-peripheral retina, identified as the region most responsive to myopic defocus.

Powerful

Second, defocus segments in the treatment zone with a higher defocus power (increased from +3.50D to +4.50D) enable a stronger myopic defocus signal to the near-peripheral retina.

Extended

Third, the number of defocus segments has increased from 396 to 630, with a corresponding expansion of the treatment zone from 33 mm to 41 mm. This ensures extensive coverage of the child’s peripheral visual field with myopic defocus signal, even for larger frames. Taken together, these enhancements represent a shift toward a more physiologically targeted approach, aligning optical design with known retinal mechanisms.

A STRUCTURED CLINICAL DEVELOPMENT ANALYSIS

A notable aspect of MiyoSmart iQ is the structured evidence pathway used during development. Rather than relying solely on a single efficacy trial, the analysis evaluated visual performance, physiological response, and clinical efficacy in a sequential manner.

Phase I: Visual Performance and Adaptation. The first phase focused on visual performance and wearability. Clinical assessments demonstrated that visual acuity, accommodation, binocular vision, and overall adaptation remained comparable to both first-generation DIMS lenses and single-vision lenses.

Phase II: Physiological Response. The second phase investigated biological activity through changes in choroidal thickness. Choroidal thickening is increasingly recognised as a short-term biomarker associated with slowed axial elongation.

Early physiological responses provide important insights into the potential mechanism of action of MiyoSmart iQ. In controlled studies, the lens has been shown to induce a significant increase in choroidal thickness after a short period of wear, with changes of approximately 15.7 µm observed within two weeks.11

The magnitude and speed of this response suggest that the enhanced design of MiyoSmart iQ can generate a strong biological signal early in treatment.

While choroidal changes are not themselves a clinical endpoint, they provide supportive evidence that the lens is effectively engaging the retinal mechanisms involved in eye growth regulation.

Phase III: Clinical Efficacy. The final phase consisted of a 12-month randomised controlled clinical trial involving 202 myopic children aged four to 12 years. The study compared MiyoSmart iQ with both single-vision lenses and first-generation DIMS lenses, evaluating changes in cycloplegic spherical equivalent refraction and axial length.

Figure 6. Choroidal thickness was significantly increased after wearing MiyoSmart iQ for two weeks, by 15.69 ± 2.60 µm compared to the contralateral eyes with single vision spectacle lens as control, indicating the potential effectiveness of MiyoSmart iQ.

Figure 7. A one-way analysis of covariance between subjects revealed a significant effect of the lens group on changes in SER after controlling for baseline age and myopia (F2, 191 = 25.25, P < .001).

Figure 8. A one-way analysis of covariance between subjects revealed a significant effect of the lens group on changes in AL after controlling for baseline age and myopia (F2, 191 = 21.43, P < .001).

12-MONTH OUTCOMES

The clinical performance of MiyoSmart iQ has been evaluated in a 12-month RTC involving 202 myopic children aged four to 12 years.4 The study compared the new lens design with both single-vision lenses and first-generation DIMS lenses, with cycloplegic spherical equivalent refraction and axial length as primary and secondary outcomes.

After 12 months, the results demonstrated a level of efficacy not previously reported for spectacle lenses. Children wearing MiyoSmart iQ showed, on average, no progression of myopia, with a mean change in spherical equivalent of +0.046D compared to -0.534D in the single vision control group.4

Axial length measurements further supported these findings. The MiyoSmart iQ group exhibited an average increase of only 0.075 mm, compared to 0.346 mm in the control group.4 This level of growth is comparable to that observed in emmetropic children, suggesting that the intervention may effectively normalise eye growth patterns.12,13

From a clinical perspective, these data translate into a reduction in progression exceeding 100% for refractive error and approximately 94% for axial elongation.4 Importantly, around nine out of 10 children wearing the lens showed no clinically relevant myopia progression4 (changes in cycloplegic spherical equivalent refraction of ≥-0.50D) over the study period, indicating a high overall responder rate.

Age-Specific Considerations

Age remains one of the most important predictors of myopia progression, and the study provides valuable insights into age-dependent treatment effects.

In younger children aged four to six years, who typically exhibit faster progression, MiyoSmart iQ achieved a reduction in refractive progression of approximately 65% and a reduction in axial elongation of around 44%.4 Although lower than in older children, these outcomes are clinically meaningful and represent a significant advance, particularly given the limited evidence for spectacle-based interventions in this age group.

In children aged seven to 12 years, efficacy was substantially higher, with reductions exceeding 100% for refractive progression.4 In this group, axial growth was nearly halted, highlighting the potential for strong clinical impact when treatment is initiated during the early school years.

VISUAL PERFORMANCE AND WEARABILITY

Maintaining visual performance is essential for the success of any spectacle-based intervention. Despite the increased defocus intensity, MiyoSmart iQ demonstrates visual performance comparable to MiyoSmart and single vision lenses.14

Clinical assessments have shown no clinically significant differences in visual acuity, accommodation, or binocular vision when compared to both DIMS and single-vision lenses.14 Subjective reports indicate a low frequency of visual symptoms, with most children adapting well to the lenses.

These findings are particularly relevant in paediatric populations, where comfort and ease of adaptation are critical for ensuring compliance. Consistent wear remains a key determinant of treatment success, and the ability to deliver high efficacy without compromising visual experience is a notable advantage.

PATIENT-CENTRIC IMPROVEMENTS

MiyoSmart iQ not only strengthens the treatment performance, it also brings three patientcentric improvements that enhance the everyday experience for young wearers.

Enhanced Coating

The first improvement is a new MiyoSmart iQ Spark coating, designed with children in mind and built for longterm wear. It provides enhanced scratch resistance, ensuring effective myopia control as children play, learn, and grow.

Freeform Technology

The second improvement is the backside aspheric option with freeform technology, that reduces visual distortions and provides clearer vision in everyday life. These are not only spectacle lenses that perform well; they also look more appealing, especially for children with moderate to stronger prescriptions.

Figure 9a. Adjusted means are estimated marginal means from two-way ANCOVA, controlling for baseline SER. Error bars denote standard errors. Statistical significance: ns = not significant, P > 0.05; * = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001; **** = P ≤ 0.0001.

Figure 9b. Adjusted means are estimated marginal means from two-way analysis of covariance, controlling for baseline SER. Error bars denote standard errors. Statistical significance: ns = not significant, P > 0.05; * = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001; **** = P ≤ 0.0001.

Extended Power Range

And finally, MiyoSmart iQ introduces an extended power range, from +2.00D to -13.00D in spherical equivalent, and up to -4.00D cylinder. This wider range allows eye care professionals to address a broader spectrum of prescriptions, including anisometropic cases.

CLINICAL IMPLICATIONS

The introduction of MiyoSmart iQ has several practical implications for optometrists and other eye care professionals. The demonstrated efficacy in children as young as four years supports earlier intervention,4 which is widely recognised as critical in reducing long-term risk.

The improved consistency of response, reflected in the high proportion of children showing no progression, addresses one of the key limitations of earlier treatments. By more effectively targeting the near-peripheral retina, the lens may reduce variability and provide more predictable outcomes.

At the same time, the magnitude of the treatment effect suggests that MiyoSmart iQ may serve as an effective monotherapy in many cases, simplifying management strategies for both clinicians and families.

CONCLUSION

MiyoSmart iQ with DIMS TED technology represents a significant evolution in spectacle-based myopia control, combining established optical principles with a deeper understanding of retinal physiology. By specifically targeting the near-peripheral retina through its triple enhanced design, the lens delivers a stronger, more consistent myopic defocus signal aligned with the mechanisms managing eye growth.

The results of the 12-month RCT set a new benchmark for efficacy, demonstrating the potential not only to slow, but to halt myopia progression in a majority of children aged four to 12 years.4 As further data become available, particularly from long-term and real-world studies, MiyoSmart iQ may redefine expectations for what spectacle lenses can achieve in myopia control.

This article is sponsored by HOYA Vision Care.

AI assistance: AI was used to assist with drafting and refining this article. The concepts, structure, clinical interpretation, and final content were developed through considerable human involvement. All clinical data, statistics, and references have been independently verified by the author against the cited source materials.

References
1. Lam CSY, Tang WC, To CH. Defocus incorporated multiple segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020 Mar;104(3):363-368. doi: 10.1136/bjophthalmol-2018-313739.
2. Lam CSY, Tang WC, To CH, et al. Long term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci Rep. 2023;13:5475. doi: 10.1038/s41598-023-32700-7.
3. Leung TW, Yam CSY, Vlasak N, et al. Comparison of myopia progression in individuals wearing defocus incorporated multiple segments (DIMS) spectacle lenses for eight years versus shorter durations. Invest. Ophthalmol. Vis. Sci. 2025;66(8):2820.
4. Tse DYY, Hon Y, Lam CSY, et al. Myopia control efficacy of defocus incorporated multiple segments spectacle lenses with triple enhanced design: a 12 month randomised controlled trial. Paper presented at The Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, Colorado, United States.
5. Holden BA, Fricke TR, Resnikoff S, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042. doi: 10.1016/j.ophtha.2016.01.006.
6. Whayeb Y, Wolffsohn JS, Logan NS, Santodomingo-Rubido J, IMI-global trends in myopia management attitudes and strategies in clinical practice – A nine-year review. Cont Lens Anterior Eye. 2026 Feb;49(1):102492. doi: 10.1016/j.clae.2025.102492.
7. Smith EL 3rd, Arumugam B, Sankaridurg P, et al. Eccentricity-dependent effects of simultaneous competing defocus on emmetropization in infant rhesus monkeys. Vision Res. 2020 Dec;177:32-40. doi: 10.1016/j.visres.2020.08.003.
8. Troilo D, Smith EL 3rd, Jones L, et al. IMI – Report on experimental models of emmetropization and myopia. Invest Ophthalmol Vis Sci. Feb 28;60(3):M31-M88. doi: 10.1167/iovs.18-25967.
9. Swiatczak B, Scholl HPN, Schaeffel F, et al. Retinal ‘sweet spot’ for myopia treatment. Sci Rep. 2024;14:26773. doi: 10.1038/s41598-024-78300-x.
10. Ostrin LA, Harb E, Wildsoet CF, et al. IMI – The dynamic choroid: new insights, challenges, and potential significance for human myopia. Invest Ophthalmol Vis Sci. 2023;64(6):4. doi: 10.1167/iovs.64.6.4.
11. Chun RKM, Liu K, Tse DYY, et al. Short term effect of second generation defocus incorporated multiple segments spectacle lenses on choroidal thickness in children. Invest Ophthalmol Vis Sci. 2025;66:2147.
12. Kaymak H, Graff B, Schwahn H, et al. Emmetropes augenlängenwachstum als therapieziel der myopieversorgung [Emmetropic eye growth as treatment goal for myopia management]. Ophthalmologe. 2022 May;119(5):528-529. German. doi: 10.1007/s00347-021-01569-0.
13. Schaeffel F, Swiatczak B. Mechanisms of emmetropization and what might go wrong in myopia. Vision Res. 2024 Jul;220:108402. doi: 10.1016/j.visres.2024.108402.
14. Lam CSY, Liu K, To CH, et al. Evaluation of the visual performance of modified defocus incorporated multiple segments spectacle lens designs. Invest Ophthalmol Vis Sci. 2025;66:5194.